Daily Cardiology Research Analysis
Analyzed 180 papers and selected 3 impactful papers.
Summary
Analyzed 180 papers and selected 3 impactful articles.
Selected Articles
1. Systems Biology Identifies TARS2 as a Cardiomyocyte Regulator of Mitochondrial Oxidative Stress in Dilated Cardiomyopathy.
Using multi-modal transcriptomics and machine learning, the study identifies TARS2 as a cardiomyocyte-enriched driver of mitochondrial oxidative stress in human DCM. Gain- and loss-of-function experiments show TARS2 promotes ROS and apoptosis, while its inhibition restores mitochondrial function and improves cardiac performance, highlighting a translational target.
Impact: This work uncovers a novel, cardiomyocyte-specific regulator of mitochondrial dysfunction in DCM with in vivo rescue upon inhibition, advancing mechanistic understanding and offering a therapeutic entry point.
Clinical Implications: While preclinical, TARS2 represents a tractable node to modulate mitochondrial oxidative stress in DCM. It supports biomarker development and informs targeted therapeutic strategies aiming to preserve cardiomyocytes.
Key Findings
- TARS2 is consistently up-regulated in human DCM hearts and associates with apoptotic signaling and macrophage crosstalk.
- TARS2 overexpression induces mitochondrial dysfunction and excessive mitochondrial ROS, leading to cardiomyocyte apoptosis.
- Genetic inhibition of TARS2 restores mitochondrial function, reduces apoptosis, and improves cardiac performance in vivo.
Methodological Strengths
- Integration of bulk, single-cell, and spatial transcriptomics with machine learning.
- Bidirectional functional validation (overexpression and genetic inhibition) with in vivo cardiac performance readouts.
Limitations
- Primarily preclinical evidence; human data are associative rather than interventional.
- Safety, specificity, and druggability of TARS2 targeting remain untested in humans.
Future Directions: Validate TARS2 as a therapeutic target in large-animal DCM models; develop selective inhibitors or RNA-based strategies; assess circulating biomarkers reflecting TARS2 activity for patient stratification.
Dilated cardiomyopathy (DCM), a leading cause of heart failure, is characterized by progressive cardiomyocyte (CM) loss and mitochondrial dysfunction; yet, the molecular drivers of mitochondrial oxidative stress (MitOS) remain unclear. By integrating bulk, single-cell, and spatial transcriptomics with machine learning, we identified threonyl-tRNA synthetase 2 (TARS2) as a CM-enriched regulator of MitOS. TARS2 was consistently up-regulated in human DCM hearts and associated with apoptotic signaling and enhanced macrophage crosstalk. Functional studies demonstrated that TARS2 overexpression disrupted mitochondrial homeostasis, triggered excessive mitochondrial reactive oxygen species, and induced CM apoptosis, whereas genetic inhibition restored mitochondrial function, reduced apoptosis, and improved cardiac performance. These findings uncover TARS2 as a novel regulator of mitochondrial dysfunction and pathological remodeling in DCM, providing both mechanistic insights and therapeutic implications, and establish a systems biology framework for translational discovery of disease targets in cardiovascular medicine.
2. Timeliness of Transthyretin Cardiac Amyloidosis Diagnosis in the Medicare Population.
In 7770 Medicare beneficiaries with both heart failure and ATTR-CM, the median time from HF diagnosis to ATTR-CM diagnosis was 494 days, and 840 days from initial loop diuretic to ATTR-CM. Female sex and common cardiopulmonary comorbidities predicted delayed diagnosis, whereas older age, atrial fibrillation, and carpal tunnel syndrome were associated with earlier identification.
Impact: Quantifying diagnostic delays and their predictors at scale directly informs earlier case-finding strategies for a treatable cardiomyopathy with evolving disease-modifying therapy.
Clinical Implications: Clinicians should maintain a high index of suspicion for ATTR-CM in HF patients—especially women and those with aortic stenosis, COPD, CAD, diabetes, or hypertension—and consider earlier targeted testing (e.g., bone scintigraphy, strain imaging, or amyloid biomarkers) instead of prolonged diuretic escalation.
Key Findings
- Median 494 days from first HF diagnosis to first ATTR-CM diagnosis; 840 days from first loop diuretic to ATTR-CM in those treated.
- Predictors of delayed diagnosis included female sex (OR 1.28), aortic stenosis (OR 1.39), COPD (OR 1.18), CAD (OR 1.26), diabetes (OR 1.21), and hypertension (OR 1.28).
- Older age (OR 0.68), atrial fibrillation (OR 0.39), and carpal tunnel syndrome (OR 0.85) were associated with lower odds of delayed diagnosis.
Methodological Strengths
- Large, national cohort using Medicare fee-for-service data (n=7770) with robust multivariable adjustment.
- Clear operational definition of diagnostic delay and prespecified clinical predictors.
Limitations
- Claims-based cohort susceptible to misclassification and unmeasured confounding; imaging/biopsy confirmation not captured.
- Lack of granular clinical phenotyping (e.g., echocardiographic strain patterns) and provider behavior data.
Future Directions: Test EHR-based alerts and structured diagnostic pathways to shorten time-to-diagnosis and assess impact on initiation of ATTR-CM therapies and outcomes, with attention to sex differences.
IMPORTANCE: Timely diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) is critical for early treatment to reduce morbidity and mortality, yet the timeliness of contemporary ATTR-CM diagnosis remains poorly understood. OBJECTIVE: To describe the time from incident heart failure (HF) diagnosis to ATTR-CM diagnosis and identify predictors of delayed diagnosis among Medicare beneficiaries. DESIGN, SETTING, AND PARTICIPANTS: This was a cohort study using US Medicare fee-for-service data from January 2016 to December 2022. Medicare fee-for-service beneficiaries with HF and ATTR-CM were included. Data were analyzed from November 2024 to July 2025. EXPOSURES: HF diagnosis with ATTR-CM diagnosis following HF diagnosis or within 1 year prior. MAIN OUTCOMES AND MEASURES: The primary outcome was time to ATTR-CM diagnosis, measured as the number of days between each patient's first HF diagnosis and first ATTR-CM diagnosis. Multivariable logistic regression assessed demographic, clinical, and socioeconomic factors associated with delayed ATTR-CM diagnosis (defined as >6 months from HF diagnosis to ATTR-CM diagnosis). RESULTS: A total of 7770 patients with HF and ATTR-CM were identified in the Medicare dataset. The median (IQR) age at the time of ATTR-CM diagnosis was 81 (76-86) years; 5995 enrollees (77%) were men. The median (IQR) time from HF diagnosis to ATTR-CM diagnosis was 494 (63-1340) days. For the 6175 patients with a loop diuretic prescription before ATTR-CM diagnosis, the median (IQR) time between initial loop prescription and ATTR-CM diagnosis was 840 (252-1768) days. After adjustment, older age (odds ratio [OR], 0.68; 95% CI, 0.63-0.74), history of atrial fibrillation (OR, 0.39; 95% CI, 0.33-0.49), and carpal tunnel syndrome (OR, 0.85; 95% CI, 0.74-0.97) were associated with lower odds of delayed diagnosis. Female sex (OR, 1.28; 95% CI, 1.13-1.45), a history of aortic stenosis (OR 1.39; 95% CI, 1.20-1.62), chronic obstructive pulmonary disease (OR, 1.18; 95% CI, 1.03-1.34), coronary artery disease (OR, 1.26; 95% CI, 1.13-1.40), diabetes (OR, 1.21; 95% CI, 1.07-1.37), and hypertension (OR, 1.28; 95% CI, 1.13-1.45) were associated with higher odds of delayed diagnosis. CONCLUSIONS AND RELEVANCE: There were substantial delays between incident HF and diagnosis of ATTR-CM found in this study. Female sex and having a history of aortic stenosis, coronary artery disease, diabetes, hypertension, or chronic obstructive pulmonary disease, which are each associated with cardiomyopathy and breathlessness, were associated with delayed diagnosis. These findings highlight the need for a heightened index of suspicion for ATTR-CM in patients with other possible etiologies of cardiomyopathy or HF symptoms.
3. Cardiomyocyte-Derived Apelin Rescues Viral Myocarditis-Induced Cardiac Lymphatic Dysfunction and Remodeling.
In a mouse model of coxsackievirus B3-induced myocarditis, cardiomyocyte-derived apelin preserves cardiac lymphatic vessel integrity and drainage, reducing inflammation and improving cardiac function via AKT-mediated stabilization of lymphatic junctional proteins. Disrupting VEGFR3 signaling blunted benefits, underscoring lymphatic dependence.
Impact: Reveals a mechanistic link between cardiomyocyte-derived apelin and cardiac lymphatic function in viral myocarditis, nominating the lymphatic axis as a therapeutic target.
Clinical Implications: Although preclinical, findings suggest apelin-based or lymphatic-targeted therapies could augment inflammation resolution and functional recovery in viral myocarditis.
Key Findings
- Acute viral myocarditis in mice induces pathological lymphangiogenesis and impairs cardiac lymphatic drainage, exacerbating inflammation and dysfunction.
- Cardiomyocyte-specific apelin overexpression restores cardiac lymphatic vessel integrity and drainage, improving inflammation and cardiac function.
- Apelin enhances lymphatic endothelial junction stability via AKT signaling (cadherin and ZO-1), and VEGFR3 blockade partially abrogates benefits.
Methodological Strengths
- In vivo viral myocarditis model with functional lymphatic assessments and cardiac phenotyping.
- Mechanistic dissection of AKT-mediated junction stabilization and pharmacologic modulation of VEGFR3 signaling.
Limitations
- Mouse model findings may not fully generalize to human viral myocarditis.
- Therapeutic feasibility and dosing strategies for apelin in humans remain undefined.
Future Directions: Test apelin agonists or lymphatic-boosting strategies in large-animal myocarditis; evaluate biomarkers of cardiac lymphatic function in patients; explore combinational antivirals plus lymphatic support.
Recent research has indicated that cardiac lymphatic vessels (CLVs) serve as a direct drainage route into the mediastinal lymph nodes for inflammation resolution. However, the role of CLVs in coxsackievirus B3-induced acute viral myocarditis (AVMC) remains unknown. In this study, we found that AVMC in mice promoted pathological cardiac lymphangiogenesis while impairing CLV-mediated drainage, leading to heart inflammation and dysfunction. Overexpression of apelin in cardiomyocytes improved CLV integrity and promoted effective lymph drainage to decrease inflammatory responses and enhance cardiac function. In vitro studies revealed that apelin stabilizes lymphatic endothelial cadherin and zonula occludens 1 to enhance lymphatic function via the AKT signaling pathway. Moreover, pre-existing lymphatic defects induced by blocking vascular endothelial growth factor receptor 3 partially diminished the benefits of cardiomyocyte-derived apelin overexpression in AVMC. Taken together, these data indicate that functional CLVs restored by cardiomyocyte-derived apelin facilitate inflammation resolution and improve heart dysfunction in AVMC. Thus, CLV-based therapeutic strategies may serve as a novel approach for alleviating AVMC heart damage.